RxDoctor Payments Data

Jonathan Rehberg, MD

Obstetrics & Gynecology · Sylacauga, ALNPI 1124067053

Payments from drug & device makers

$4,903in general payments, 2019–2025

Across 169 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AbbVie$746
  • Astellas Pharma US Inc$366
  • Takeda Pharmaceuticals U.S.A., Inc.$310
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$298
  • Pfizer$286
  • plus $961 from 19 others

What the payments were for

  • Travel & lodging$1613%
  • Food & beverage$2,98661%
  • Education$1,75636%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,903 in reported general payments places this provider in the 85th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$7,841
Medicare patients
34
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated36$16,835
MyrbetriqMirabegron20$14,154
OsphenaOspemifene13$4,145
Estradiol144$3,609
ValacyclovirValacyclovir Hcl54$2,548
YuvafemEstradiol19$2,179
Raloxifene Hcl30$1,883
Solifenacin Succinate25$1,539
Medroxyprogesterone Acetate55$726
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet14$683
Estradiol (Once Weekly)Estradiol13$559
Ibandronate Sodium14$304
Paroxetine Hcl31$281
Levothyroxine Sodium14$264
Ibuprofen16$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$286$16,83536 claims
Astellas Pharma US IncMyrbetriq$366$14,15420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Sylacauga

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →